An in vitro Investigation of the Antioxidant Properties of Cannabidiol (CBD) Crystals on Sickle Cell Disease

Thumbnail Image
Journal Title
Journal ISSN
Volume Title
Saudi Digital Library
Cannabidiol or CBD is a substance derived from the Cannabis sativa plant, which is likewise acknowledged as hemp or marijuana. Cannabis plants have been utilised for medical purposes for thousands of years. However, the undesirable effects of this plant, such as hallucinogenic or psychotropic effects, have limited its use. Scientists have been able to extract CBD from Cannabis does not have the hallucinogenic or psychotropic effects of THC. Recently, CBD has been allowed for public use in a number of countries, including the UK. In addition to the many medicinal claims of CBD, here we have investigated the antioxidant properties of this substance and its impact on blood from sickle cell patients. The results were very encouraging; the moderate use of CBD may improve the quality of life of sickle cell patients. Sickle cell patients often suffer from pains and systemic inflammation, and other symptoms which result from oxidative damage to the red blood cells. CBD has antioxidant characteristics that can prevent and reduce the red blood cells from sickling, hence reducing sickle cell patients suffering. This study has medical, societal and economic values. Adult sickle cell patients can purchase CBD and use it straight away for its safety as it is legal to use in the UK without prescription. Improvements in the health of sickle cell patients is beneficial, not only for patients, but also for society, particularly for patients families, schools and public facilities. Also, it is possible to lessen treatments costs for patients and ministries of health by reducing hospital admissions. Furthermore, the use of CBD could lead to an increase in the number of producers of this product. This will help to create a balance between supply and demand to deliver the CBD at an economical cost for the patients besides the creation of new jobs in producers. Although CBD was discovered first the time approximately 50 years ago, it is still considered a new agent. Within the last two decades, there has been a large increase in the number of studies evaluating CBD as a therapeutic agent. These studies have explored various health benefit outcomes for multiple conditions; nevertheless, no studies have investigated the impacts of CBD on sickle cells. This study opened a new research field and could create a new scientific wave to promote investigation into the effects of CBD on sickle cells using different ages and races and exactly how it works on sickle cells. It is concluded that CBD has promising therapeutic tools for sickle cell disease